Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT Academic Article Article uri icon


MeSH Major

  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Preoperative Care
  • Tomography, X-Ray Computed


  • Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindered. Alternative strategies for the investigation of new agents in patients with GCT should be considered, particularly when studying the efficacy and relative toxicity of platinum analogues.

publication date

  • November 1992



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/BF00944190

PubMed ID

  • 1336770

Additional Document Info

start page

  • 327

end page

  • 30


  • 10


  • 4